ContributorsPublishersAdvertisers

Alicia Morgans, MD, MPH, on the Rationale for Examining the Clinical and Cost Impact of Cabazitaxel in mCRPC

cancernetwork.com
 2021-10-11

Cover picture for the articleCancerNetwork® sat down with Alicia Morgans MD, MPH, at the 2021 European Society for Medical Oncology Congress to talk about the rationale for analyzing the financial impact of cabazitaxel vs a second androgen receptor targeted agent in metastatic castration-resistant prostate cancer. At the 2021 European Society of Medical Oncology...

www.cancernetwork.com

Comments / 0

Comments / 0